Auflistung nach Autor "Packer, Milton"

Sortiert nach: Sortierung: Ergebnisse:

  • Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial 
    Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Khan, Muhammad Shahzeb; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Brunner-La Rocca, Hans Pieter; Choi, Dong-Ju; Chopra, Vijay; Chuquiure-Valenzuela, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L.; Gonzalez-Juanatey, Jose R.; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio Víctor; Piña, Ileana L.; Ponikowski, Piotr; Senni, Michele; Seronde, Marie-France; Sim, David; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragos; Zhang, Jian; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet; Brueckmann, Martina; Pocock, Stuart J.; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2020-12)
    Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the ...
  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure 
    Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James L.; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed; Kimura, Karen; Schnee, Janet; Zeller, Cordula; Cotton, Daniel; Bocchi, Edimar; Böhm, Michael; Choi, Dong-Ju; Perrone, Sergio Víctor; EMPEROR-Reduced Trial Investigators (Massachusetts Medical Society, 2020-10-08)
    Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects ...
  • Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial 
    Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Waheed, Jamal; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; Jyothis, George; Brueckmann, Martina; Zannad, Faiez; Packer, Milton; EMPEROR-Preserved Trial Committees and Investigators (Wiley, 2019-09-16)
    Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory ...
  • Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF 
    Vaduganathan, Muthiah; Claggett, Brian L.; Desai, Akshay S.; Anker, Stefan D.; Perrone, Sergio Víctor; Janssens, Stefan; Milicic, Davor; Arango, Juan L.; Packer, Milton; Shi, Victor C.; Lefkowitz, Martin P.; McMurray, John J.V.; Solomon, Scott D. (Elsevier, 2020-01-28)
    Background: The period shortly after hospitalization for heart failure (HF) represents a high-risk window for recurrent clinical events, including rehospitalization or death. Objectives: This study sought to determine ...

DSpace Suche

Stöbern

Mein Benutzerkonto